Arrowhead Pharmaceuticals Inc (ARWR)

Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell

$15.40

Buy

$15.50

arrow-up$0.37 (+2.41%)

Arrowhead Pharmaceuticals Inc is a biotechnology company. It is engaged in the development of medicine to treat diseases such as hepatitis B, and thrombosis with a genetic origin, primarily divided by the overproduction of one or more proteins.
Prices updated at 17 May 2025, 00:44 EDT
| Prices minimum 15 mins delay
|
Prices in USD
NASDAQ
arrow-up0.52%
NASDAQ
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
Our Investment Fees and Charges.
Sector
Healthcare
Industry
Biotechnology
Chairman
Dr. Christopher Anzalone,PhD
CEO
Dr. Christopher Anzalone,PhD
Most recent earnings
30 Sep 2024
Fiscal year end
30 Sep 2024
Employees
609
Head office
177 E Colorado Boulevard
Pasadena
United States
91105
mobile
+1 626 304-3400
letter
ir@arrowheadpharma.com
computer
Company website

Key personnel

Owner nameSalaryBonusAll other compensationTotal compensationRestricted stock award
Mr. Douglas S. Ingram,Esq.
Independent Director
-----
Dr. Douglass Given, PhD
Chairman of the Board
0.10m--0.48m-
Mr. Daniel Apel
Chief Financial Officer
-----
Dr. Michael S. Perry, PhD
Independent Director
0.08m--0.46m-
Dr. Christopher Anzalone,PhD
Chairman of the Board, Chief Executive Officer and President
0.95m--12.42m-
Mr. James Hamilton
Chief of Discovery and Translational Medicine
0.57m--3.49m-
Dr. Mauro Ferrari, PhD
Independent Director
0.08m--0.46m-
Dr. Adeoye Olukotun, M.D.,M.P.H.
Independent Director
0.08m--0.46m-
Mr. William D. Waddill
Lead Independent Director
0.09m--0.47m-
Mr. Patrick C. O'Brien
Chief Operating Officer, General Counsel and Corporate Secretary
0.61m--3.93m-
Dr. Hongbo Lu, PhD
Independent Director
0.04m--0.42m-
Ms. Victoria Vakiener
Independent Director
0.08m--0.46m-

Top 5 shareholders

Owner nameNo. of sharesShare as % of port.Last changePortfolio % changeDate of portfolio% Total assets
BlackRock Inc19,926,1540.00533374815423.16821630 Apr 202514.43
BlackRock Fund Advisors13,861,5321.24678-4928983-30 Apr 202510.04
Vanguard Group Inc13,202,5620.0030410182738.35726230 Apr 20259.56
venBio Select Advisor LLC11,111,1112.20954--30 Apr 20258.05
Avoro Capital Advisors LLC8,888,888-8888888-30 Apr 20257.14

Director dealings

DateActionNamePriceValueNo. of sharesHolding (%)Additional info
27 Dec 2024-Dr. Adeoye Y. Olukotun, M.D.20.0057,00036,740--
23 Dec 2024-Dr. Christopher Anzalone,PhD19.59246,1093,775,772--
18 Dec 2024-Dr. Adeoye Y. Olukotun, M.D.22.99384,69239,590--
18 Dec 2024-Dr. Michael S. Perry, PhD22.99384,692131,490--
18 Dec 2024-Dr. Christopher Anzalone,PhD20.52259,6403,702,394--
18 Dec 2024-Dr. Christopher Anzalone,PhD--3,788,335--
18 Dec 2024-Dr. Christopher Anzalone,PhD22.12128,2743,688,335--
18 Dec 2024-Dr. Christopher Anzalone,PhD21.74179,5723,694,134--
18 Dec 2024-Dr. Mauro Ferrari22.99384,69277,514--
18 Dec 2024-Mr. William D. Waddill22.99384,69257,111--
18 Dec 2024-Dr. Hongbo Lu, PhD22.99384,69247,163--
18 Dec 2024-Ms. Victoria Vakiener22.99384,69237,944--
16 Dec 2024-Douglas B. Given,PhD21.90109,500124,714--
17 Dec 2024-Douglas B. Given,PhD22.0412,056124,167--
17 Dec 2024-Mr. William D. Waddill22.0482,58440,378--
16 Dec 2024-Mr. William D. Waddill21.9082,08144,125--
16 Dec 2024-Ms. Victoria Vakiener21.91197,05921,211--
22 Mar 2024-Dr. Hongbo Lu, PhD28.0011,20034,080--
25 Sep 2024-Dr. Hongbo Lu, PhD--30,430--
18 Apr 2024-Dr. Hongbo Lu, PhD22.0011,00036,080--
Please note that past performance is not a reliable indicator of future returns.


Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2025 Morningstar. All rights reserved.